crossover
    1999

    The use of stabilized NADH in chronic fatigue syndrome: a randomized, double-blind, placebo-controlled study

    Forsyth LM, Preuss HG, MacDowell AL

    Published in Annals of Allergy, Asthma & Immunology

    Key Findings

    31% of patients responded favourably to NADH 10 mg/day versus 8% on placebo over four weeks in chronic fatigue syndrome.

    Conclusions

    Small early crossover signal for fatigue.

    Limitations

    Small sample, short crossover, subjective endpoint.

    Supplements Studied

    NADH
    Compound

    31% of chronic fatigue syndrome patients responded to NADH versus 8% on placebo over four weeks.

    Related Health Concerns

    Chronic Fatigue Syndrome (ME/CFS)
    Chronic Fatigue

    Study Details

    Year:1999
    Sample Size:26
    Duration:4 weeks
    Quality Score:4/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.